address1,address2,city,zip,country,phone,fax,website,industry,industryKey,industryDisp,sector,sectorKey,sectorDisp,longBusinessSummary,companyOfficers,auditRisk,boardRisk,compensationRisk,shareHolderRightsRisk,overallRisk,governanceEpochDate,compensationAsOfEpochDate,executiveTeam,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,dividendRate,dividendYield,exDividendDate,payoutRatio,fiveYearAvgDividendYield,beta,trailingPE,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,tradeable,enterpriseValue,profitMargins,floatShares,sharesOutstanding,heldPercentInsiders,heldPercentInstitutions,impliedSharesOutstanding,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,lastSplitFactor,lastSplitDate,enterpriseToRevenue,enterpriseToEbitda,52WeekChange,SandP52WeekChange,lastDividendValue,lastDividendDate,quoteType,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,debtToEquity,revenuePerShare,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,symbol,language,region,typeDisp,quoteSourceName,triggerable,customPriceAlertConfidence,hasPrePostMarketData,firstTradeDateMilliseconds,marketState,regularMarketPrice,regularMarketChange,regularMarketDayRange,fullExchangeName,averageDailyVolume3Month,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekChangePercent,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,earningsCallTimestampStart,earningsCallTimestampEnd,isEarningsDateEstimate,epsTrailingTwelveMonths,epsForward,epsCurrentYear,priceEpsCurrentYear,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,sourceInterval,exchangeDataDelayedBy,averageAnalystRating,cryptoTradeable,regularMarketChangePercent,corporateActions,regularMarketTime,exchange,messageBoardId,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,market,esgPopulated,shortName,longName,trailingPegRatio
Glenmark House,"B.D. Sawant Marg Chakala, Off Western Express Highway Andheri (East)",Mumbai,400099,India,91 22 4018 9999,91 22 4018 9986,https://www.glenmarkpharma.com,Drug Manufacturers - Specialty & Generic,drug-manufacturers-specialty-generic,Drug Manufacturers - Specialty & Generic,Healthcare,healthcare,Healthcare,"Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and sells generics, specialty products, and OTC pharmaceutical products in India, North America, Latin America, Europe, and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology, respiratory, oncology, cardiology, diabetic, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topical products, drops, and respiratory/MDI/DPI/nasal sprays. Its product pipeline includes ISB 2001, a BCMA x CD38 x CD3 trispecific engagement by antibodies based on the T cell receptor trispecific antibody, which is in Phase 1 clinical trial for indication of relapsed/refractory multiple myeloma; ISB 1442, a CD38 x CD47 bispecific engagement by antibodies based on the T cell receptor biparatopic bispecific antibody that is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma and acute myeloid leukemia; and GRC 65327, a Cbi-b inhibitor, which is in pre-clinical study for the indication of solid tumors. The company's pipeline also comprises ISB 880, an IL-1RAP antagonist monoclonal antibody, which is in Phase 1 clinical trial for the treatment of autoimmune diseases; and ISB 830, a telazorlimab OX40 antagonist antibody that is in Phase 2 clinical trial for the treatment of atopic dermatitis. In addition, the company offers Ryaltris nasal spray for the treatment of seasonal allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.","[{'maxAge': 1, 'name': 'Mr. Glenn Mario Saldanha', 'age': 54, 'title': 'Chairman, MD & CEO', 'yearBorn': 1970, 'fiscalYear': 2024, 'totalPay': 168610000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Cherylann Maria Pinto B.Pharm', 'age': 57, 'title': 'Executive Director of Corporate Services & Executive Director', 'yearBorn': 1967, 'fiscalYear': 2024, 'totalPay': 60840000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Harish Vinayak Kuber', 'title': 'Company Secretary & Compliance Officer', 'fiscalYear': 2024, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Alind  Sharma', 'age': 53, 'title': 'President and Chief Human Resources Officer', 'yearBorn': 1971, 'fiscalYear': 2024, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Ulhas R. Dhuppad', 'age': 57, 'title': 'President & Head of Global Pharmaceutical Development', 'yearBorn': 1967, 'fiscalYear': 2024, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Indrajit  Bose', 'title': 'President & Chief Quality Officer', 'fiscalYear': 2024, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Brijlal  Motwani', 'title': 'President & Global Head of Formulation Operations', 'fiscalYear': 2024, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Alok  Malik', 'title': 'President & Business Head of India Formulations', 'fiscalYear': 2024, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Christoph  Stoller', 'title': 'President and Business Head of Europe & Emerging Markets', 'fiscalYear': 2024, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Marc T. Kikuchi B.A., M.B.A.', 'age': 55, 'title': 'President & Business Head of North America', 'yearBorn': 1969, 'fiscalYear': 2024, 'exercisedValue': 0, 'unexercisedValue': 0}]",2,6,10,1,7,1748736000,1735603200,[],86400,2,1639.2,1633.9,1625.0,1645.5,1639.2,1633.9,1625.0,1645.5,2.5,0.15,1726185600,0.0674,0.41,0.196,44.175438,38.528717,1156671,1156671,889901,943714,943714,0.0,0.0,0,0,462061666304,1199.3,1830.95,3.43912,1458.702,1522.0618,2.5,0.0015251343,INR,False,484063182848,0.07794,146501156,282200992,0.49624002,0.30121002,283028992,304.497,5.3750935,1743379200,1774915200,1743379200,10470970368,37.05,42.48,2:1,1189382400,3.603,19.637,0.33203316,0.094471335,2.5,1726185600,EQUITY,1636.7,2011.0,1300.0,1678.4166,1695.0,1.75,buy,12,17052279808,58.675,24651030528,24726669312,0.846,1.558,134354616320,27.943,476.164,0.08136,0.12543,90821197824,-15374954496,-8275950080,-0.161,0.67598,0.18348,0.13694,INR,GLENMARK.NS,en-US,US,Equity,Delayed Quote,True,HIGH,False,1025495100000,POSTPOST,1636.7,-2.5,1625.0 - 1645.5,NSE,889901,437.3999,0.36471266,1199.3 - 1830.95,-194.25,-0.10609247,33.203316,1747997940,1754996340,1755345600,1748228400,1748228400,True,37.05,42.48,61.03511,26.815712,177.99792,0.12202487,114.63818,0.075317696,15,15,1.8 - Buy,False,-0.15251343,[],1750413599,NSI,finmb_2529483,Asia/Kolkata,IST,19800000,in_market,False,GLENMARK PHARMACEUTICALS,Glenmark Pharmaceuticals Limited,
